Amanta Healthcare shares list 7% higher on NSE; IPO investors pocket ₹16,000 per lot
- 9th September 2025
- 12:30:00 PM
- 3 min read
Summary
Amanta Healthcare made a strong stock market debut with shares listing at a 7% premium on NSE, valuing the company at about ₹520 crore. IPO investors pocketed gains of ₹16,000 per lot, following an 82x subscription frenzy. With fresh capital earmarked for sterile injectables expansion, the real test will be execution and margin delivery — making this more than just a listing-day pop.
Mumbai | September 9 – Investors who bet on Amanta Healthcare’s IPO are smiling on debut day. The pharma company’s shares hit the market on September 9 at ₹135 on NSE, giving a 7% premium to the issue price of ₹126 — translating into ₹16,065 gains per lot of 119 shares.
The debut valued Amanta Healthcare at around ₹520 crore, almost in line with grey market whispers. On the National Stock Exchange (NSE), the stock opened at ₹135, a 7.14% premium over the issue price of ₹126. On the BSE, shares debuted at ₹134, reflecting a 6.35% premium. At listing, the company’s market capitalisation stood at approximately ₹520 crore, broadly aligned with grey market expectations.
For retail investors allotted one lot of 119 shares, this translated into ₹16,000+ gains per lot on listing day.
But is this just a listing-day pop — or does the story go deeper?
Also Read: A Fed cut, a Nifty breakout, and FIIs on the run- says Vikram Kasat- Head of Advisory, PL Capital
Subscription and IPO details
The IPO, priced in a band of ₹120–126 per share, was open between September 1–3 and saw an overall subscription of 82.6 times. Demand was robust across categories: retail investors bid 54.9 times, non-institutional investors subscribed 209.4 times, and qualified institutional buyers applied 35.9 times.
The ₹126 crore issue was a pure fresh issue with no promoter exit. Proceeds will be used to establish a new SteriPort line, expand capacity for small volume parenterals (SVPs), and cover general corporate expenses.
Amanta also raised ₹37.8 crore from anchor investors, with participation from Bandhan Small Cap Fund, Sunrise Investment Trust, and Aarth Growth Fund.
Outlook for investors
Headquartered in Ahmedabad, Amanta Healthcare manufactures sterile injectables and medical devices, catering to domestic and export markets. The company’s capacity expansion, backed by IPO proceeds, is expected to strengthen its position in a niche, high-demand segment.
While the 7% premium listing delivered quick gains for IPO investors, market experts suggest new investors track execution of expansion plans and margin performance before entering. IPO stocks typically see volatility in the initial sessions, and the stock’s medium-term trajectory will depend on earnings visibility and sector demand.
Amanta Healthcare’s successful listing adds momentum to recent SME and healthcare IPOs, underscoring investor appetite for specialty pharma plays with growth potential.
Also Read: Finance Minister Nirmala Sitharaman on GST Reform
PL Capital
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.
